Heart septal defects refer to abnormalities in the septum, the wall that separates the chambers of the heart. The heart comprises four chambers, consisting of two atria (upper chambers) and two ventricles (lower chambers).. In some cases, there can be openings or holes in the septum, leading to a condition known as a septal defect. There are two main types of heart septal defects: atrial septal defects (ASD) and ventricular septal defects (VSD). ASD occurs when there is a hole between the atria, allowing blood to flow between them. VSD, on the other hand, involves a hole in the septum between the ventricles, allowing blood to pass from the left to the right side of the heart. These defects can disrupt the normal blood flow, causing various symptoms such as fatigue, shortness of breath, and, in severe cases, heart failure. Treatment options vary depending on the size and location of the defect, ranging from medications to surgical interventions. Early detection and appropriate management are crucial for improving outcomes in individuals with heart septal defects. Regular medical check-ups and diagnostic tests can aid in the timely identification and intervention for this condition.
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India